Fatty Acids, Omega-6.

Omega-6 and omega-3 fatty acids compete for the same delta-6 desaturase, elongase and delta-5 desaturase, and for the same positions in membrane phospholipids. A high omega-6 intake lowers the conversion of alpha-linolenic acid onward and shifts eicosanoid substrate toward arachidonic acid.

EPA and arachidonic acid compete as substrate for the same oxygenase enzymes and for membrane incorporation. The ratio of the two, not either alone, sets which family of signalling lipids is produced.

DHA and arachidonic acid occupy the same sn-2 position of membrane phospholipids, so raising one lowers the other. Membrane composition is the mechanism behind the ratio mattering.

Preformed EPA and DHA displace omega-6 fatty acids from membranes and from the desaturase queue. Formulators balance the two rather than stacking omega-6 on an already high background intake.

Linoleic acid is converted to gamma-linolenic acid by delta-6 desaturase, the rate-limiting step of the omega-6 chain. Supplying GLA bypasses that step and moves the pathway toward dihomo-gamma-linolenic acid.

Evening primrose oil carries both linoleic acid and preformed GLA, so it sits one step down the same pathway. It is the long-standing way to feed the omega-6 chain past the desaturase bottleneck.

Borage seed oil is the densest common GLA source and enters the omega-6 chain downstream of linoleic acid. Pairing raises dihomo-gamma-linolenic acid without relying on desaturase capacity.

Polyunsaturated fatty acids have multiple double bonds that are oxidation-prone, and alpha-tocopherol is the chain-breaking antioxidant that sits in the membrane with them. Vitamin E requirement rises with polyunsaturated fat intake, which is why oils are formulated with tocopherol.

Mixed tocopherols protect the double bonds of polyunsaturated oils both in the capsule and in the membrane after absorption. This is standard practice in polyunsaturated oil formulation.

Delta-6 desaturase activity depends on adequate zinc status, so low zinc slows the conversion of linoleic acid onward. Supplying the mineral supports the step the fatty acid depends on.

Pyridoxine is described as a cofactor in the desaturation and elongation of essential fatty acids. It is routinely included with GLA-bearing oils for that reason.

Astaxanthin spans the lipid bilayer and quenches radicals at both membrane surfaces, where polyunsaturated chains are most exposed. It is formulated with polyunsaturated oils to slow peroxidation.

Linoleic acid is the parent omega-6 fatty acid and the dominant component of most omega-6 sources. Counting both entries separately overstates the total intake.

Delta-6 desaturase, the first and slowest step converting linoleic acid onward to gamma-linolenic acid, requires magnesium along with zinc and pyridoxal phosphate. Where any of those cofactors is short, the conversion step slows and the pathway backs up at linoleic acid. This is settled enzymology rather than a supplement claim.

Biotin is the cofactor for acetyl-CoA carboxylase and is required for normal fatty acid synthesis and elongation. Biotin status also affects the desaturation steps that move linoleic acid along the omega-6 pathway. Its role here is permissive, which is different from adding to an effect.

The desaturase complex depends on cytochrome b5 reductase, a flavoprotein that carries a riboflavin-derived FAD group to shuttle electrons. Without adequate riboflavin the electron supply to the desaturation step is limited. The effect is on pathway throughput, measured biochemically.

Glutathione peroxidases are selenoenzymes that reduce lipid hydroperoxides, the first products formed when a polyunsaturated fatty acid is attacked by oxygen. The more polyunsaturated fat sits in a membrane, the more that clean-up capacity is called on. Selenium status therefore shapes how well an omega-6-rich intake is handled oxidatively.

Tocotrienols sit in the membrane lipid layer and interrupt the chain reaction of lipid peroxidation at the propagation step, the same job alpha-tocopherol does with a different tail chemistry. Polyunsaturated omega-6 fatty acids carry several bis-allylic positions and are the most oxidation-prone lipids in the membrane. The pairing is standard for that reason.

Rosemary extract, standardised for carnosic acid and rosmarinic acid, is a common in-oil antioxidant used to hold back rancidity in polyunsaturated oils. It protects the product in the bottle rather than doing anything in the body. Peroxide value and anisidine value are what this is measured against.

Alpha-linolenic acid from flaxseed and linoleic acid from omega-6 oils compete for the same delta-6 desaturase and the same elongase enzymes. A high linoleic acid intake reduces conversion of alpha-linolenic acid onward to EPA, and the same is true in the other direction. This competition is the basis for looking at the ratio of the two families rather than either alone.

EPA and DHA from krill oil displace arachidonic acid from membrane phospholipid positions and compete with it for cyclooxygenase and lipoxygenase. The eicosanoids produced from the omega-3 substrate differ in their signalling profile from those made from arachidonic acid. Membrane fatty acid composition is the measured endpoint, which is a marker.

Omega-6 fatty acids do not circulate mainly as free acids; they are esterified into phospholipids, with linoleate and arachidonate concentrated at the sn-2 position of phosphatidylcholine. That is the pool phospholipase A2 draws from when eicosanoid signalling is triggered. Supplying phosphatidylcholine supplies both the carrier and, depending on source, some of the fatty acid itself.

Sunflower lecithin is itself rich in linoleic acid bound into its phospholipids, so it contributes omega-6 as well as acting as the emulsifier. In softgels and emulsions it keeps the oil phase dispersed. Both roles are compositional facts about the material rather than an effect claim.

Curcumin has been reported to reduce cyclooxygenase-2 and lipoxygenase activity in cell and animal work, which are the enzymes that act on arachidonic acid derived from the omega-6 pathway. That places it downstream of where omega-6 intake feeds in. The human evidence for a combined effect is limited, and most of the mechanism comes from non-human models.

Boswellic acids act on 5-lipoxygenase, the enzyme that converts arachidonic acid to the 4-series leukotrienes. That is a direct point of contact with the omega-6 pathway's downstream products. The mechanism is well characterised in vitro; how much of it carries into people at ordinary supplement doses is less settled.

Salicin from willow bark is converted to salicylic acid, which acts on cyclooxygenase and therefore on the prostaglandins made from arachidonic acid. Anyone combining a salicylate source with a high omega-6 intake is acting on the same pathway from two directions. Platelet function is one of the things cyclooxygenase governs, which is worth flagging in any combination that also includes omega-3 oils.